

Sweetened beverage intake and risk of latent autoimmune diabetes in adults (LADA) and type 2 diabetes

Josefin E Löfvenborg¹, Tomas Andersson^{1,2}, Per-Ola Carlsson³, Mozghan Dorkhan⁴, Leif Groop⁴, Mats Martinell⁵, Tiinamaija Tuomi⁶, Alicja Wolk¹ and Sofia Carlsson¹

¹Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ²Center for Occupational and Environmental Medicine, Stockholm County Council, Stockholm, Sweden, ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁴Department of Clinical Sciences, Lund University, Malmö, Sweden, ⁵Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden, and ⁶Endocrinology, Abdominal Centre, Helsinki University Hospital, Research Program for Diabetes and Obesity, University of Helsinki, and Finnish Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland

Correspondence should be addressed to J E Löfvenborg
Email
josefin.lofvenborg@ki.se

Abstract

Objective: Sweetened beverage intake is associated with increased risk of type 2 diabetes, but its association with autoimmune diabetes is unclear. We aimed to investigate sweetened beverage intake and risk of latent autoimmune diabetes in adults (LADA); autoimmune diabetes with features of type 2 diabetes.

Design/methods: Data from a Swedish population-based study was used, including incident cases of LADA ($n=357$) and type 2 diabetes ($n=1136$) and randomly selected controls ($n=1371$). Diabetes classification was based on onset age (≥ 35), glutamic acid decarboxylase autoantibodies (GADA) and C-peptide. Sweetened beverage intake information was derived from a validated food frequency questionnaire. ORs adjusted for age, sex, family history of diabetes, education, lifestyle, diet, energy intake and BMI were estimated using logistic regression.

Results: Daily intake of >2 servings of sweetened beverages (consumed by 6% of participants) was associated with increased risk of LADA (OR: 1.99, 95% CI: 1.11–3.56), and for each 200 mL daily serving, OR was 1.15 (95% CI: 1.02–1.29). Findings were similar for sugar-sweetened (OR: 1.18, 95% CI: 1.00–1.39) and artificially sweetened beverages (OR: 1.12, 95% CI: 0.95–1.32). Similarly, each daily serving increment in total sweetened beverage conferred 20% higher type 2 diabetes risk (95% CI: 1.07–1.34). In type 2 diabetes patients, high consumers displayed higher HOMA-IR levels (4.5 vs 3.5, $P=0.0002$), but lower HOMA-B levels (55 vs 70, $P=0.0378$) than non-consumers. Similar tendencies were seen in LADA.

Conclusions: High intake of sweetened beverages was associated with increased risk of LADA. The observed relationship resembled that with type 2 diabetes, suggesting common pathways possibly involving insulin resistance.

European Journal of
Endocrinology
(2016) 175, 605–614

Introduction

Sugar-sweetened beverage intake has been linked to increased risk of type 2 diabetes in numerous studies (1, 2, 3, 4, 5, 6); the most recent meta-analysis found that the risk increases by 13% for an increment of each serving per day in intake (7). Suggested routes by which sugar-sweetened beverages may influence diabetes risk are through glycemic or insulinemic responses or by

contributing to excessive energy intake (8, 9). Artificially sweetened beverages have also been associated with an increased risk of type 2 diabetes (1, 10), although they contain no calories and are thus adding neither to the glycemic load nor to the total daily energy intake (11). Suggested mechanisms related to artificially sweetened beverages include enhanced appetite by distortion of

satiety signaling (11) and deteriorated glucose tolerance provoked by alterations in gut microbiota (12).

The association between sweetened beverages and autoimmune diabetes is less clear (13, 14), but a recent study suggests that intake of sugar-sweetened beverage may increase the risk of type 1 diabetes in genetically susceptible individuals (13). Possible mechanistic pathways for its involvement in autoimmune processes include induced beta cell apoptosis (15), which could be due to toxic levels of glucose (16), induced oxidative stress (17) or an overloaded beta cell possibly leading to it being more visible to the immune system (18).

Latent autoimmune diabetes in adults (LADA) is a hybrid form of diabetes with features of both type 1 and type 2 diabetes. In addition to sharing autoimmune markers (typically glutamic acid decarboxylase antibodies (GADA)) with type 1 diabetes patients, LADA patients also present with (mild to moderate) insulin resistance, a feature shared with type 2 diabetes (19). Thus, it is possible that intake of sweetened beverages may influence the risk of LADA through mechanisms related to either autoimmune processes or insulin resistance, but this remains to be explored. LADA accounts for 9% of all adult-onset diabetes (20) and therefore constitutes an important part of the diabetes spectrum. Still, potential risk factors remain largely unexplored.

We aimed to investigate the risk of LADA and type 2 diabetes in relation to intake of sugar-sweetened and artificially sweetened beverage and to explore how it relates to markers of insulin resistance, beta cell function and autoimmunity.

Subjects and methods

Study population and design

Analyses were based on data from the ESTRID study (Epidemiological Study of Risk Factors for LADA and Type 2 Diabetes), a Swedish population-based case-control study initiated in 2010 (Supplementary Fig. 1, see section on supplementary data given at the end of this article) (21). ESTRID is a sub-study to ANDIS (All New Diabetics in Scania; <http://andis.ludc.med.lu.se>), which is a large study aiming to characterize all new diabetes cases within the county of Scania (southern Sweden, 1.3 million inhabitants) with regard to diabetes type, clinical features and genotype. LADA constitutes 5% of all diabetes in the ANDIS Registry, all ages included (22). All newly diagnosed cases of LADA identified in ANDIS since 2010 have been invited to participate in the ESTRID study, together with a

random sample of incident type 2 diabetes cases in ANDIS (4:1 ratio to LADA cases). Since 2012, ESTRID has also recruited cases of LADA and type 2 diabetes from ANDiU (All New Diabetics in Uppsala; <http://www.andiu.se/>), a study using the ANDIS setup but covering the county of Uppsala (in mid-Sweden, 350000 inhabitants). The Swedish Population Register was used to select a random sample of controls who was free of diabetes, aged ≥ 35 years and matched to the cases based on participation date and county (incidence density sampling (23)) in a 6:1 ratio to LADA cases. A self-administered questionnaire including a large number of questions on health and lifestyle factors was sent by mail to all cases and controls. Participants included in this study were recruited in ESTRID between September 2010 and July 2015. The participation rate was 81% for cases and 66% for controls.

The current analysis excluded those with incomplete information on exposure ($n=26$) or any of the main covariates (family history of diabetes, education, physical activity, smoking, alcohol intake and BMI; $n=53$). We further excluded individuals with reported total daily energy intake that deviated more than 3 s.d. from the \log_e -transformed sex-specific mean energy intake ($n=7$ women and $n=11$ men). After exclusions, 357 cases of LADA, 1136 cases of type 2 diabetes and 1371 controls remained for analysis (96% of included cases were recruited from ANDIS and 4% from ANDiU). Informed consent was provided by all participants. The study has been approved by the Regional Ethical Review Board at Karolinska Institutet, Stockholm, Sweden.

Serological assays

C-peptide was measured by the Cobas e 601 analyzer (Roche Diagnostics) or IMMULITE 2000 (Siemens Healthcare Diagnostics Product). GADA was quantitatively determined using ELISA (enzyme immunoassay; RSR Limited, Cardiff, UK). ELISA gives a maximum value of 250 IU/mL and has a sensitivity of 84% and specificity of 98% for a cutoff level of 10.7 IU/mL (24).

Case definition

All diabetes cases were diagnosed by a physician within the regional health care system. Classification into diabetes subtype was based on fasting blood samples collected at the time of diagnosis. Criteria for LADA diagnosis were age ≥ 35 years, GADA positivity (≥ 10 IU/mL) and serum C-peptide exceeding the lower limit

for the normal range as specified by the manufacturer (≥ 0.2 nmol/L for IMMULITE and ≥ 0.3 nmol/L for Cobas). Type 2 diabetes criteria were ≥ 35 years, GADA negativity (< 10 IU/mL) and C-peptide levels above > 0.6 nmol/L (IMMULITE) or > 0.72 nmol/L (Cobas). There are no unified criteria for LADA diagnosis and classification, but the criteria used in this study are in line with previous literature (19). The exception is C-peptide, which in this study is used as an indicator of remaining insulin production to separate LADA from type 1 diabetes. It replaces the insulin therapy criterion (i.e. no insulin therapy within 6–12 months of diagnosis) that is commonly used, but to some extent, open to subjectivity because it reflects the assessment made by the treating physician. Homeostatic Model Assessment for insulin resistance (HOMA-IR) and beta cell function (HOMA-B) were calculated based on fasting plasma glucose and C-peptide levels at diagnosis (25).

Dietary assessment

Information on sweetened beverage intake was obtained from a semi-quantitative Food Frequency Questionnaire (FFQ) consisting of 132 items. The participants were asked to report their habitual food intake during the preceding year. The cases were specifically instructed to report their average intake during the year before diagnosis. Four questions were asked about sweetened beverage intake: cola, other soft drinks/soda, diet cola and other diet soft drinks/soda. The participants were asked to report their average number of 200 mL servings per day or per week. 'Other soft drink/soda' also refers to other sweetened beverages such as nectars and diluted syrups. The FFQ includes a separate question on 100% fruit juice, which was not evaluated in this study.

Information on potentially confounding dietary factors was also derived from the FFQ. Nutritional data from the Swedish National Food Agency database were used to estimate the average daily intakes of total energy and nutrients based on the FFQ.

The FFQ has been validated against 24-h recall interviews (26), diet records (27) and dietary biomarkers (28). Validation of individual food items against four 1-week diet records in a subsample of 129 women indicated a correlation of 0.6 for FFQ-reported sweetened beverage intake (A Wolk, unpublished results). The FFQ-based nutrient estimates have been validated in comparison with the mean of fourteen 24-h recall interviews in 248 men, and showed Spearman correlation coefficients ranging from 0.44 (protein) to 0.81 (alcohol) (26).

Other covariate assessment

BMI at age 20 and at present was calculated based on self-reported height and weight. Education was assessed with a question of the highest attained level of education and categorized into elementary school, high school or university. Family history of diabetes was categorized as yes/no for any type of diabetes in first-degree relatives. Leisure time physical activity during the preceding year was assessed by a question with four response options ranging from sedentary to regularly active. Smoking habits were categorized as never smoker, former or current smoker. Estimated total alcohol intake was categorized into non-consumption, 0.01–4.9 g/day, 5.0–14.9 g/day and ≥ 15.0 g/day.

Statistical analysis

Conditional logistic regression model was used to estimate the odds ratios (OR) and 95% confidence intervals (CI) of LADA and type 2 diabetes in relation to sweetened beverage intake. We analyzed not only the total intake but also performed separate analysis for sugar-sweetened and artificially sweetened beverages. One serving was defined as 200 mL, and exposure was assessed as continuous as well as categorical (< 1 , 1–2 and > 2 servings per day) with non-consumers as reference. ORs are presented after adjustment for age and sex (model 1), and with additional adjustment for education, family history, physical activity, smoking, alcohol intake, total energy intake (kcal/day) and the following dietary factors in grams per day: vegetables, fruit, whole grain, fatty fish, red/processed meat, biscuits/sweets/salty snacks and coffee (servings/day) (model 2). Current BMI was considered to potentially be in the causal pathway and was included separately in the model (model 3). Results of model 3 are presented in the text, unless otherwise specified. Stratified analyses were performed using BMI and GADA levels (LADA) respectively. Sensitivity analyses included restricting the analysis to cases who participated within six months of diagnosis and to those not being on dietary treatment to minimize reverse causation. To investigate whether the association between highly sweetened beverage consumption and diabetes reflects increased thirst before diagnosis, we assessed the association between water consumption and risk of LADA/type 2 diabetes.

Because of the incidence density sampling design, the estimated ORs could be interpreted as incidence rate ratios (23). Two-sided *P* values were calculated using χ^2 (proportions) or Wilcoxon–Mann–Whitney test

(means and medians). All analyses were performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA).

Results

Clinical characteristics

Mean age was 58.8 years for LADA patients, 63.2 years for type 2 diabetes patients and 58.5 years for controls (Table 1). Patients with LADA had lower BMI and were less insulin resistant, but had worse beta cell function and were more often treated with insulin after diagnoses compared with type 2 diabetes patients. Family history of diabetes was almost as common in LADA (45%) as in type 2 diabetes (50%), but less frequent among controls (24%). Median diabetes duration on the date of participation was 7.5 months for LADA and 5.3 months for type 2 diabetes (data not shown in table).

Lifestyle characteristics by category of sweetened beverage consumption

The proportion of participants (irrespective of case/control status) who were non-consumers of both sugar-sweetened and artificially sweetened beverages was 63%. High consumers of total sweetened beverages (>2 servings per day of sugar-sweetened beverages and artificially sweetened beverages) had considerably higher BMI than other consumers and the largest annual weight gain (1.05% vs 0.72% in non-consumers) since age 20 (Table 2). In addition, they had generally less favorable lifestyle compared with those consuming little or no sweetened beverages, including higher prevalence of

smoking, low physical activity, lower consumption of vegetables, fruit, fatty fish and whole grains and higher consumption of red/processed meat and biscuits/sweets/salty snacks. Comparing high consumers of sugar-sweetened vs artificially sweetened beverages suggests that the latter group reported lower total energy intake but tended to have higher BMI both at present and at age 20 (Supplementary Table 1).

LADA and sweetened beverage consumption

The risk of LADA was increased 2-fold (OR: 1.99, 95% CI: 1.11–3.56) for the group consuming more than two servings of sweetened beverages per day compared with non-consumers (Table 3), whereas no excess risk was seen in consumers of up to two servings per day. At consumption levels exceeding five servings per day (7 cases/6 controls), an OR of 4.47 (95% CI: 1.21–16.47) was observed. Each increment of daily serving conferred a 15% increased risk (OR: 1.15, 95% CI: 1.02–1.29). The results were similar in a more refined analysis of sugar-sweetened and artificially sweetened beverage intake separately, with an OR of 1.18 (95% CI: 1.00–1.39) and OR of 1.12, (95% CI: 0.95–1.32) respectively, per daily serving.

Stratifying the analyses by sex, age, family history of diabetes, BMI and median GADA levels (191IU/mL) of the LADA patients indicated that the excess risk in high consumers of sweetened beverages was consistent across most subgroups (Supplementary Fig. 2). However, the increased risk of LADA was primarily seen in men, but analysis of women was based on a very limited number of high consumers (6 cases/19 controls).

Table 1 Characteristics of LADA and type 2 diabetes cases from ANDIS/ANDiU and controls participating in ESTRID, 2010–2015. Data are presented as mean (s.d.) unless otherwise stated.

	Controls	LADA	Type 2 diabetes	P ^a
<i>n</i>	1371	357	1136	
Age (years)	58.5 (13.3)	58.8 (12.5)	63.2 (10.3)	<0.0001
Sex (% women)	53	47	40	0.0117
BMI (kg/m ²)	25.9 (4.0)	28.2 (5.4)	31.1 (5.4)	<0.0001
Overweight (BMI ≥25) (%)	54	71	93	<0.0001
Obese (BMI ≥30) (%)	14	32	51	<0.0001
Family history of diabetes (% yes)	24	45	50	0.0813
Insulin treatment (%) ^b	–	42	6	<0.0001
Metformin and/or sulfonylurea treatment (%) ^b	–	55	62	0.0198
HOMA-IR, median (interquartile range) ^b	–	2.7 (1.8–4.4)	3.5 (2.7–4.9)	<0.0001
HOMA-B, median (interquartile range) ^b	–	39 (14–69)	68 (42–92)	<0.0001
GADA, median (interquartile range) (IU/mL)	–	191 (27–250)	–	–

^aP for difference between LADA and type 2 diabetes. ^bThe information is only available for LADA and type 2 diabetes patients.

Type 2 diabetes and sweetened beverage consumption

The OR of type 2 diabetes was increased by 2.39 (95% CI: 1.39–4.09) in those consuming more than two servings of sweetened beverages per day compared with non-consumers (Table 3). Consumption of more than five servings per day (18 cases/6 controls) was associated with an OR of 10.53 (95% CI: 2.75–40.33). The risk of type 2 diabetes was increased by 20% for each daily serving increment (OR: 1.20, 95% CI: 1.07–1.34). Similar findings were seen when assessing sugar-sweetened (OR: 1.21, 95% CI: 1.05–1.41) and artificially sweetened beverages (OR: 1.18, 95% CI: 1.01–1.38) separately. The excess risk in high consumers was seen across subgroups of sex, age, family history of diabetes and BMI (Supplementary Fig. 3).

HOMA-IR, HOMA-B and GADA

Median HOMA-IR tended to be higher among high consumers of sweetened beverages (>2 servings per day) compared with that among non-consumers for LADA (3.7 vs 2.5, $P=0.0561$), and more clearly shown for type 2 diabetes patients (4.5 vs 3.5, $P=0.0002$). In contrast, there was a tendency of lower HOMA-B levels among high consumers compared with that among non-consumers in

the LADA patient group (20 vs 48, $P=0.0588$ for median). This difference was more pronounced among type 2 diabetes patients (55 vs 70, $P=0.0378$). No difference in GADA levels was observed in high consumers compared with that in non-consumers (250 vs 204, $P=0.6511$) among LADA patients.

Sensitivity analyses

The results were unchanged when using occupation instead of education as an indicator for socioeconomic status. Sensitivity analysis conducted to explore reverse causation indicated similar results; when restricting the analysis to patients responding to the questionnaire within six months of diagnosis, the excess risk among high (>2 servings per day) consumers persisted for both LADA (OR: 2.74, 95% CI: 1.16–6.47) and type 2 diabetes (OR: 2.02, 95% CI: 1.09–3.74). For type 2 diabetes in which we had larger number of cases, we could further restrict the analysis to cases responding within three months and observed a similar association (OR: 3.18, 95% CI: 1.13–8.95). Exclusion of patients reporting that they were on dietary treatment while filling out the questionnaire indicated similar results for LADA (OR: 2.01, 95% CI: 1.07–3.78) and type 2 diabetes (OR: 2.15, 95% CI: 1.21–3.83).

Table 2 Characteristics of participants in ESTRID by intake of sweetened beverages. Data are presented as mean (s.d.) unless otherwise stated.

	Total sweetened beverage intake (no. of 200 mL servings/day)				P
	0	<1	1–2	>2	
Mean intake (g/day)	0	76	287	890	(Highest vs lowest)
n (%)	1815 (63)	587 (20)	302 (11)	160 (6)	
Sugar-sweetened beverage (g/day)	0 (0)	46 (44)	148 (146)	461 (676)	<0.0001
Artificially sweetened beverage (g/day)	0 (0)	30 (44)	139 (153)	429 (424)	<0.0001
Age (years)	63.0 (11.4)	55.2 (11.8)	58.6 (13.6)	52.6 (11.6)	<0.0001
Sex (% women)	50	46	38	33	<0.0001
High level of education (% university)	29	31	22	14	<0.0001
BMI current (kg/m ²)	27.8 (5.1)	28.4 (5.7)	29.1 (5.1)	30.8 (6.9)	<0.0001
BMI at age 20 (kg/m ²) ^a	21.7 (3.1)	22.0 (3.5)	22.4 (3.2)	23.3 (4.0)	<0.0001
Average yearly weight gain (%) since age 20 ^a	0.72 (0.62)	0.88 (0.77)	0.89 (0.74)	1.05 (0.82)	<0.0001
Physically inactive (%)	16	17	26	30	<0.0001
Family history of diabetes (% yes)	37	39	31	42	0.1793
Smoking status (% current)	18	22	26	34	<0.0001
Alcohol (g/day)	8.8 (9.8)	8.8 (9.4)	7.5 (10.2)	6.9 (9.1)	0.0049
Coffee (servings/day)	3.2 (2.3)	3.2 (2.2)	2.9 (2.3)	2.7 (2.4)	0.0043
Vegetables (g/day)	218 (146)	205 (115)	196 (159)	157 (110)	<0.0001
Fruits (g/day)	162 (128)	146 (112)	153 (124)	115 (116)	<0.0001
Red or processed meat (g/day)	87 (51)	102 (52)	107 (65)	118 (63)	<0.0001
Fatty fish (g/day)	22 (20)	20 (19)	21 (17)	16 (14)	<0.0001
Whole grain (g/day)	56 (34)	51 (30)	52 (32)	45 (33)	<0.0001
Biscuits, sweets, and salty snacks (g/day)	31 (26)	42 (30)	45 (32)	50 (38)	<0.0001
Energy (kcal/day)	1762 (557)	1900 (627)	2129 (766)	2236 (785)	<0.0001

^aMissing for 19% of participants.

Table 3 Odds ratios and 95% CIs of LADA and type 2 diabetes in relation to intake of sweetened beverages (sugar sweetened, artificially sweetened and total).

	LADA						Type 2 diabetes					
	Non-consumers			Consumers (no. of 200 mL servings/day)			Non-consumers			Consumers (no. of 200 mL servings/day)		
	<1	1-2	>2	<1	1-2	>2	<1	1-2	>2	<1	1-2	>2
Sugar-sweetened beverage												
Cases/controls	268/1029			53/239			26/85			18-Oct		
Model 1	1	0.88 (0.63-1.24)	1.16 (0.72-1.84)	1.94 (0.87-4.32)	1	0.76 (0.59-0.98)	0.94 (0.66-1.35)	3.81 (2.07-7.00)	66/85	44/18	3.81 (2.07-7.00)	
Model 2	1	0.95 (0.66-1.35)	1.15 (0.69-1.91)	2.11 (0.87-5.12)	1	0.75 (0.56-1.00)	0.84 (0.56-1.24)	3.45 (1.74-6.83)	1	1	3.45 (1.74-6.83)	
Model 3	1	0.95 (0.66-1.36)	1.02 (0.61-1.71)	2.20 (0.90-5.36)	1	0.75 (0.55-1.03)	0.68 (0.44-1.05)	3.17 (1.45-6.93)	1	1	3.17 (1.45-6.93)	
Model 3 (continuous)	1	1.18 (1.00-1.39) per 200 mL serving/day			1	1.21 (1.05-1.41) per 200 mL serving/day			1	1	1.21 (1.05-1.41) per 200 mL serving/day	
Artificially sweetened beverage												
Cases/controls	289/1151			34/121			20/75			14/24		
Model 1	1	1.16 (0.77-1.75)	1.13 (0.67-1.90)	2.47 (1.24-4.90)	1	1.61 (1.19-2.18)	1.27 (0.86-1.86)	4.41 (2.48-7.82)	58/75	42/24	4.41 (2.48-7.82)	
Model 2	1	1.10 (0.71-1.69)	1.06 (0.62-1.82)	2.06 (1.01-4.20)	1	1.53 (1.09-2.14)	1.16 (0.76-1.79)	3.54 (1.91-6.54)	1	1	3.54 (1.91-6.54)	
Model 3	1	1.04 (0.67-1.62)	0.92 (0.53-1.61)	1.90 (0.91-3.97)	1	1.47 (1.00-2.14)	0.86 (0.53-1.39)	2.42 (1.19-4.92)	1	1	2.42 (1.19-4.92)	
Model 3 (continuous)	1	1.12 (0.95-1.32) per 200 mL serving/day			1	1.18 (1.01-1.38) per 200 mL serving/day			1	1	1.18 (1.01-1.38) per 200 mL serving/day	
Total sweetened beverage												
Cases/controls	213/880			79/297			40/147			25/47		
Model 1	1	1.17 (0.86-1.58)	1.17 (0.80-1.73)	2.30 (1.36-3.91)	1	1.17 (0.94-1.47)	1.21 (0.91-1.61)	4.12 (2.69-6.29)	115/147	88/47	4.12 (2.69-6.29)	
Model 2	1	1.17 (0.85-1.61)	1.19 (0.78-1.81)	2.12 (1.20-3.75)	1	1.11 (0.86-1.42)	1.10 (0.80-1.51)	3.31 (2.07-5.31)	1	1	3.31 (2.07-5.31)	
Model 3	1	1.13 (0.82-1.56)	1.02 (0.66-1.56)	1.99 (1.11-3.56)	1	1.05 (0.79-1.39)	0.79 (0.55-1.13)	2.39 (1.39-4.09)	1	1	2.39 (1.39-4.09)	
Model 3 (continuous)	1	1.15 (1.02-1.29) per 200 mL serving/day			1	1.20 (1.07-1.34) per 200 mL serving/day			1	1	1.20 (1.07-1.34) per 200 mL serving/day	

Cases/controls indicate how the total number of LADA cases ($n=357$), type 2 diabetes cases ($n=1136$) and controls ($n=1371$) were distributed between the four categories of intake. Model 1: Age and sex. Model 2: Model 1 + education, family history of diabetes, physical activity, smoking, alcohol, coffee, vegetables, fruit, red/processed meat, fatty fish, snacks, wholegrain, total energy intake + mutual adjustment for sugar-sweetened/artificially sweetened beverages. Model 3: Model 2 + BMI.

Finally, there was no association between water consumption (as an indicator of excessive thirst during the year before diagnosis caused by hyperglycemia) and risk of neither LADA (OR: 0.98, 95% CI: 0.94–1.02 per daily serving) nor type 2 diabetes (OR: 0.99, 95% CI: 0.96–1.03).

Discussion

High intake of sweetened beverages was associated with an increased risk of LADA; a two-fold increased risk was seen in consumers of more than two 200mL servings per day, and each daily serving increment in sweetened beverage intake conferred a 15% increased risk. High consumers also experienced a two-fold increased risk of type 2 diabetes and a 20% risk increase per serving, which is consistent with findings in a recent meta-analysis of prospective data (7). The associations were similar in separate analyses of sugar-sweetened and artificially sweetened beverages for the risk of LADA as well as type 2 diabetes, which has also been previously suggested for type 2 diabetes (8).

Proposed mechanisms by which sugar-sweetened beverage intake may increase diabetes risk are predominantly related to induced insulin resistance (29) and include decrease in hepatic insulin sensitivity (30), adverse effects of increased insulin demand due to high intermittent spikes in blood glucose levels (16) and increase in inflammatory markers such as C-reactive protein (31). Another possibility is that the increased risk is mediated by increases in overweight (32). In line with previous studies on type 2 diabetes (1, 3, 5, 7, 8), the observed positive association remained after adjustment for BMI, possibly suggesting a direct adverse effect of sweetened beverage intake on glucose homeostasis. However, it could be that the BMI does not fully indicate the level of visceral fat, which is a predictor of type 2 diabetes (33). An effect on the development of autoimmunity is also possible. Sugar-sweetened beverages have previously been linked to type 1 diabetes (13) as well as rheumatoid arthritis (34), with suggestions of sugar being involved in causing infections and/or inflammation (34). In this study, high consumption of sweetened beverages was associated with insulin resistance and low beta cell function in type 2 diabetes patients, with similar tendencies in LADA, whereas no association with GADA levels was observed. A link between sugar-sweetened beverage intake and HOMA-IR was previously reported in adolescents (35, 36). Hence, the most plausible explanation may be that the excess risk of LADA among high consumers of sweetened beverages is related to mechanisms involving insulin

resistance or other pathophysiological features shared with type 2 diabetes. The findings are also supportive of the accelerator hypothesis, in which it is postulated that beta cell stress caused by insulin resistance activates the immune system and consequently accelerates beta cell apoptosis leading to manifest diabetes. The intensity of the immune response, and hence the tempo of beta cell destruction, is suggested to be modulated by genetic susceptibility conferred by HLA genes (37).

We also found an excess risk in high consumers of artificially sweetened beverages, which is in line with previous studies in type 2 diabetes (1, 7). Although not containing sugars and thus not contributing to caloric intake, it has been suggested that artificially sweetened beverages may stimulate appetite, which may lead to positive energy balance and weight gain (38). Further, artificial sweeteners have also been hypothesized to have adverse effects on abdominal fat (39) and gut microbiota (12), which may induce glucose intolerance. Alternatively, one could speculate that consumers of artificially sweetened beverages may have swapped from sugar-sweetened beverages to prevent further weight gain (39). In that case, we may actually be assessing diabetes risk related to previous high consumption of sugar-sweetened beverages. In line with this explanation, we found the highest BMI, both at present and age 20, in the group reporting high intakes of artificially sweetened beverages.

The main strength of this study is the population-based design, with a large number of incident LADA patients, and the use of a FFQ that has been thoroughly validated against both biomarkers (28) and 24-h recall interviews (26), together with information on a wide variety of potential confounding factors. For sweetened beverage intake, correlation with diet records showed good agreement (A Wolk, unpublished results), but unfortunately there is no biomarker of such intake. Validation of the FFQ questions has been performed in another setting, and a number of years ago, however, the validation studies included both men and women who were all within the same age range as participants of this study.

The main limitation is the retrospective design that may lead to recall bias. However, for a rare disease like LADA, the case-control design is far more efficient than the corresponding prospective study, which would have required an unrealistically large sample and/or follow-up time to yield the same number of cases. In this study, patients were meticulously instructed to report their dietary habits as they were before diabetes diagnosis, but some patients may have reduced their

consumption of sweetened beverages since diagnosis and report accordingly. Still, this would not lead us to overestimate the risk in high consumers, but rather the opposite. The fact that the patients were asked to recall their consumption of sweetened beverages as they were before diagnosis, whereas the controls were asked to recall their intake during the year directly before participation date, may introduce bias. In an attempt to minimize such recall bias, analysis were run separately for patients filling out the questionnaire within six months and three months of diagnosis, and excluded those who were treated by diet modification, but the results were similar. Some controls may have undiagnosed diabetes. This would make controls more similar to the cases with regard to lifestyle and hence dilute the true associations between intake of sweetened beverages and diabetes risk. Bias would be introduced if the participating controls are not representative of the population generating the cases, i.e. inhabitants of the counties of Scania and Uppsala, with regard to both sweetened beverage intake and other covariates. In a comparison using data of the general population, we found that the participating controls are equivalent with regard to educational level (data from Statistics Sweden, www.scb.se).

One could also speculate that the high consumption of sweetened beverages reported by patients reflects greater thirst in the period preceding diagnosis due to hyperglycemia. This is difficult to assess, but we noted that these patients did not report excess intake of water. Finally and most importantly for the credibility of these findings with regard to type 2 diabetes, our results were in line with previous reports based on prospective data with diet reported a several years before diagnosis (1, 3). False-positive LADA patients, i.e. truly type 2 diabetes (i.e. GADA negative) patients, but misclassified as LADA, could drive the results for LADA in the same direction as that of type 2 diabetes. However, this is unlikely to fully explain the observed association for LADA considering the high specificity of the GADA assay and the fact that the same magnitude of association was also observed among LADA patients with high GADA levels. Another explanation for our findings could be that high intake of sweetened beverages simply is a marker of an overall poor lifestyle leading onto the trajectory toward diabetes onset. We did observe that high consumers had an unhealthier lifestyle in general, and the highest BMI, both currently and at age 20, and the greatest weight gain since age 20. The excess risk in high consumers did persist after adjustment for a wide range of dietary and lifestyle factors including BMI, but we cannot rule out residual

confounding due to unmeasured or imprecisely measured factors, such as BMI, energy intake or socio-demographic factors, as an explanation for our results. The group of high consumers constitutes 6% of the study participants, but it is noteworthy that among participants below age 50, 12% consume such high levels.

In conclusion, these findings add support to the accumulating evidence suggesting that high intake of sweetened beverages, both sugar-sweetened and artificially sweetened, is a potential risk factor for type 2 diabetes. Importantly, these findings indicate that the adverse health effects seen with high sweetened beverage intake also encompass autoimmune forms of diabetes. The excess risk seems not to be fully explained by caloric intake or BMI, opening up for other explanations possibly including direct adverse effects of sweetened beverages on glucose homeostasis and insulin sensitivity. The suggested positive association between artificially sweetened beverages and diabetes risk remains to be further explored. This study supports the notion that dietary factors may influence LADA development (21, 40, 41). This is important as the identification of modifiable risk factors could aid in preventing autoimmune diabetes. It is especially urgent in times when diabetes prevalence is on the rise (42) and sweetened beverage consumption continues to be high (43).

Supplementary data

This is linked to the online version of the paper at <http://dx.doi.org/10.1530/EJE-16-0376>.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

The ESTRID study is financed by the Swedish Research Council (VR), the Swedish Research Council for Health, Working Life and Welfare (FORTE), AFA Insurance and the Swedish Diabetes Association. The Swedish Research Council is also supporting ANDIS (including ALF funding for clinical research in medicine) and ANDiU (including EXODIAB – strategic governmental funding for excellence of diabetes research in Sweden).

Author contribution statement

J E L contributed to the design of the study, analyzed and interpreted the data and wrote the manuscript. S C researched data, contributed to the design of the study, interpreted the data and reviewed and revised the manuscript. T A contributed to data analysis, interpretation of data and reviewing and revising of the manuscript. P-O C, M D, L G and M M researched data and contributed to reviewing and revising of the manuscript. T T and A W contributed to interpretation of data

and reviewing and revising of the manuscript. All authors have read and approved the final version of the manuscript. J E L is the guarantor of the study taking responsibility for the integrity of the data and affirming that this is a truthful report of the study.

References

- The InterAct Consortium. Consumption of sweet beverages and type 2 diabetes incidence in European adults: results from EPIC-InterAct. *Diabetologia* 2013 **56** 1520–1530. (doi: 10.1007/s00125-013-2899-8)
- Palmer JR, Boggs DA, Krishnan S, Hu FB, Singer M & Rosenberg L. Sugar-sweetened beverages and incidence of type 2 diabetes mellitus in African American women. *Archives of Internal Medicine* 2008 **168** 1487–1492. (doi:10.1001/archinte.168.14.1487)
- de Koning L, Malik VS, Rimm EB, Willett WC & Hu FB. Sugar-sweetened and artificially sweetened beverage consumption and risk of type 2 diabetes in men. *American Journal of Clinical Nutrition* 2011 **93** 1321–1327. (doi:10.3945/ajcn.110.007922)
- Schulze MB, Manson JE, Ludwig DS, Colditz GA, Stampfer MJ, Willett WC & Hu FB. Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. *JAMA* 2004 **292** 927–934. (doi:10.1001/jama.292.8.927)
- Odegaard AO, Koh WP, Arakawa K, Yu MC & Pereira MA. Soft drink and juice consumption and risk of physician-diagnosed incident type 2 diabetes: the Singapore Chinese Health Study. *American Journal of Epidemiology* 2010 **171** 701–708. (doi:10.1093/aje/kwp452)
- Ardissone Korat AV, Willett WC & Hu FB. Diet, lifestyle, and genetic risk factors for type 2 diabetes: a review from the Nurses' Health Study, Nurses' Health Study 2, and Health Professionals' Follow-up Study. *Current Nutrition Reports* 2014 **3** 345–354. (doi: 10.1007/s13668-014-0103-5)
- Imamura F, O'Connor L, Ye Z, Mursu J, Hayashino Y, Bhupathiraju SN & Forouhi NG. Consumption of sugar sweetened beverages, artificially sweetened beverages, and fruit juice and incidence of type 2 diabetes: systematic review, meta-analysis, and estimation of population attributable fraction. *BMJ* 2015 **351** h3576. (doi:10.1136/bmj.h3576)
- Greenwood DC, Threapleton DE, Evans CE, Cleghorn CL, Nykjaer C, Woodhead C & Burley VJ. Association between sugar-sweetened and artificially sweetened soft drinks and type 2 diabetes: systematic review and dose-response meta-analysis of prospective studies. *British Journal of Nutrition* 2014 **112** 725–734. (doi:10.1017/S0007114514001329)
- Malik VS, Popkin BM, Bray GA, Després JP & Hu FB. Sugar-sweetened beverages, obesity, type 2 diabetes, and cardiovascular disease risk. *Circulation* 2010 **121** 1356–1364. (doi:10.1161/CIRCULATIONAHA.109.876185)
- Nettleton JA, Lutsey PL, Wang Y, Lima JA, Michos ED & Jacobs DR Jr. Diet soda intake and risk of incident metabolic syndrome and type 2 diabetes in the Multi-Ethnic Study of Atherosclerosis (MESA). *Diabetes Care* 2009 **32** 688–694. (doi:10.2337/dc08-1799)
- Mattes RD & Popkin BM. Nonnutritive sweetener consumption in humans: effects on appetite and food intake and their putative mechanisms. *American Journal of Clinical Nutrition* 2009 **89** 1–14. (doi:10.3945/ajcn.2008.26792)
- Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S & Weinberger A *et al.* Artificial sweeteners induce glucose intolerance by altering the gut microbiota. *Nature* 2014 **514** 181–186. (doi:10.1038/nature13793)
- Lamb MM, Frederiksen B, Seifert JA, Kroehl M, Rewers M & Norris JM. Sugar intake is associated with progression from islet autoimmunity to type 1 diabetes: the Diabetes Autoimmunity Study in the Young. *Diabetologia* 2015 **58** 2027–2034. (doi:10.1007/s00125-015-3657-x)
- Pundziute-Lycká A, Persson LA, Cedermark G, Jansson-Roth A, Nilsson U, Westin V & Dahlquist G. Diet, growth, and the risk for type 1 diabetes in childhood: a matched case-referent study. *Diabetes Care* 2004 **27** 2784–2789. (doi: 10.2337/diacare.27.12.2784)
- Eizirik DL & Darville MI. β -Cell apoptosis and defense mechanisms: lessons from type 1 diabetes. *Diabetes* 2001 **50** S64–S69. (doi:10.2337/diabetes.50.2007.S64)
- Shao C, Gu J, Meng X, Zheng H & Wang D. Systematic investigation into the role of intermittent high glucose in pancreatic beta-cells. *International Journal of Clinical and Experimental Medicine* 2015 **8** 5462–5469.
- Kohnert KD, Freyse EJ & Salzsieder E. Glycaemic variability and pancreatic β -cell dysfunction. *Current Diabetes Reviews* 2012 **8** 345–354. (doi:10.2174/157339912802083513)
- Björk E, Kämpe O, Karlsson FA, Pipeleers DG, Andersson A, Hellerström C & Eizirik DL. Glucose regulation of the autoantigen GAD65 in human pancreatic islets. *Journal of Clinical Endocrinology and Metabolism* 1992 **75** 1574–1576. (doi: 10.1210/jc.75.6.1574)
- Tuomi T, Santoro N, Caprio S, Cai M, Weng J & Groop L. The many faces of diabetes: a disease with increasing heterogeneity. *Lancet* 2014 **383** 1084–1094. (doi:10.1016/S0140-6736(13)62219-9)
- Hawa MI, Kolb H, Schloot N, Beyan H, Paschou SA, Buzzetti R, Mauricio D, De Leiva A, Yderstraede K & Beck-Nielsen H *et al.* Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: action LADA 7. *Diabetes Care* 2013 **36** 908–913. (doi:10.2337/dc12-0931)
- Löfvenborg JE, Andersson T, Carlsson PO, Dorkhan M, Groop L, Martinell M, Rasouli B, Storm P, Tuomi T & Carlsson S. Coffee consumption and the risk of latent autoimmune diabetes in adults – results from a Swedish case-control study. *Diabetic Medicine* 2014 **31** 799–805. (doi: 10.1111/dme.12469)
- Lund University. ANDIS – Alla Nya Diabetiker I Skåne. 2016. (available at: <http://andis.ludc.med.lu.se/>). Accessed on August 2016.
- Vandenbroucke JP & Pearce N. Case-control studies: basic concepts. *International Journal of Epidemiology* 2012 **41** 1480–1489. (doi:10.1093/ije/dys147)
- Rahmati K, Lernmark A, Becker C, Foltyn-Zadura A, Larsson K, Ivarsson SA & Törn C. A comparison of serum and EDTA plasma in the measurement of glutamic acid decarboxylase autoantibodies (GADA) and autoantibodies to islet antigen-2 (IA-2A) using the RSR radioimmunoassay (RIA) and enzyme linked immunosorbent assay (ELISA) kits. *Clinical Laboratory* 2008 **54** 227–235.
- The Oxford Center for Diabetes, Endocrinology & Metabolism. Diabetes Trial Unit. HOMA Calculator. (available from: <http://www.dtu.ox.ac.uk/homacalculator/index.php>). Accessed on June 2013.
- Messerer M, Johansson SE & Wolk A. The validity of questionnaire-based micronutrient intake estimates is increased by including dietary supplement use in Swedish men. *Journal of Nutrition* 2004 **134** 1800–1805.
- Levitán EB, Westgren CW, Liu S & Wolk A. Reproducibility and validity of dietary glycemic index, dietary glycemic load, and total carbohydrate intake in 141 Swedish men. *American Journal of Clinical Nutrition* 2007 **85** 548–553.
- Wallin A, Di Giuseppe D, Burgaz A, Håkansson N, Cederholm T, Michaëlsson K & Wolk A. Validity of food frequency questionnaire-based estimates of long-term long-chain n-3 polyunsaturated fatty acid intake. *European Journal of Nutrition* 2014 **53** 549–555. (doi:10.1007/s00394-013-0563-1)
- Otero-Losada M, Cao G, González J, Muller A, Ottaviano G, Lillig C, Capani F, Ambrosio G & Milei J. Functional and morphological changes in endocrine pancreas following cola drink consumption in rats. *PLoS ONE* 2015 **10** e0118700. (doi:10.1371/journal.pone.0118700)
- Maki KC, Nieman KM, Schild AL, Kaden VN, Lawless AL, Kelley KM & Rains TM. Sugar-sweetened product consumption alters glucose homeostasis compared with dairy product consumption in men and women at risk of type 2 diabetes mellitus. *Journal of Nutrition* 2015 **145** 459–466. (doi:10.3945/jn.114.204503)
- Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC & Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. *American Journal of Clinical Nutrition* 2002 **75** 492–498.

- 32 Malik VS, Pan A, Willett WC & Hu FB. Sugar-sweetened beverages and weight gain in children and adults: a systematic review and meta-analysis. *American Journal of Clinical Nutrition* 2013 **98** 1084–1102. (doi:10.3945/ajcn.113.058362)
- 33 Hanley AJ, Wagenknecht LE, Norris JM, Bryer-Ash M, Chen YI, Anderson AM, Bergman R & Haffner SM. Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) Family study. *Diabetologia* 2009 **52** 2079–2086. (doi:10.1007/s00125-009-1464-y)
- 34 Hu Y, Costenbader KH, Gao X, Al-Daabil M, Sparks JA, Soloman DH, Hu FB, Karlson EW & Lu B. Sugar-sweetened soda consumption and risk of developing rheumatoid arthritis in women. *American Journal of Clinical Nutrition* 2014 **100** 959–967. (doi:10.3945/ajcn.114.086918)
- 35 Bremer AA, Aunger P & Byrd RS. Relationship between insulin resistance-associated metabolic parameters and anthropometric measurements with sugar-sweetened beverage intake and physical activity levels in US adolescents: findings from the 1999–2004 National Health and Nutrition Examination Survey. *Archives of Pediatrics and Adolescent Medicine* 2009 **163** 328–335. (doi:10.1001/archpediatrics.2009.21)
- 36 Kondaki K, Grammatikaki E, Jiménez-Pavón D, De Henauw S, González-Gross M, Sjöström M, Gottrand F, Molnar D, Moreno LA & Kafatos A *et al.* Daily sugar-sweetened beverage consumption and insulin resistance in European adolescents: the HELENA (Healthy Lifestyle in Europe by Nutrition in Adolescence) Study. *Public Health Nutrition* 2013 **16** 479–486. (doi:10.1017/S1368980012002613)
- 37 Wilkin TJ. The accelerator hypothesis. *Pediatric Diabetes* 2012 **13** 334–339. (doi:10.1111/j.1399-5448.2011.00831.x)
- 38 Blundell JE & Hill AJ. Paradoxical effects of an intense sweetener (aspartame) on appetite. *Lancet* 1986 **1** 1092–1093. (doi:10.1016/S0140-6736(86)91352-8)
- 39 Pereira MA. Diet beverages and the risk of obesity, diabetes, and cardiovascular disease: a review of the evidence. *Nutrition Reviews* 2013 **71** 433–430. (doi:10.1111/nure.12038)
- 40 Rasouli B, Andersson T, Carlsson PO, Dorkhan M, Grill V, Groop L, Martinell M, Tuomi T & Carlsson S. Alcohol and the risk for latent autoimmune diabetes in adults: results based on Swedish ESTRID study. *European Journal of Endocrinology* 2014 **171** 535–543. (doi:10.1530/EJE-14-0403)
- 41 Löfvenborg JE, Andersson T, Carlsson PO, Dorkhan M, Groop L, Martinell M, Tuomi T, Wolk A & Carlsson S. Fatty fish consumption and risk of latent autoimmune diabetes in adults. *Nutrition and Diabetes* 2014 **4** e139. (doi: 10.1038/nutd.2014.36)
- 42 World Health Organization. Global Report on Diabetes. 2016. (available at: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf?ua=1). Accessed on April 2016.
- 43 Singh GM, Micha R, Khatibzadeh S, Shi P, Lim S, Andrews KG, Engell RE, Ezzati M, Mozaffarian D & Global Burden of Diseases Nutrition and Chronic Diseases Expert Group (NutriCoDe). Global, regional, and national consumption of sugar-sweetened beverages, fruit juices, and milk: a systematic assessment of beverage intake in 187 countries. *PLoS ONE* 2015 **10** e0124845. (doi:10.1371/journal.pone.0124845)

Received 29 April 2016

Revised version received 17 August 2016

Accepted 15 September 2016